Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446158 | 1.00 | TDP1 (0.55) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL7833146 | 0.87 | TDP1 (0.51) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL31540262 | 0.86 | HSPB1 (0.51) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL1038678 | 0.85 | TDP1 (0.53) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL2369197 | 0.82 | TDP1 (0.50) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL8812343 | 0.82 | TDP1 (0.62) | TDP1ATMHSPB1ALDH1A1MAPT | |
| SCHEMBL30137606 | 0.81 | S100A4 (0.39) | TDP1ATMALDH1A1MAPTHTT | |
| SCHEMBL11302023 | 0.81 | S100A4 (0.39) | TDP1ATMALDH1A1MAPTHTT | |
| SCHEMBL17410994 | 0.81 | MAPK1 (0.53) | ALDH1A1MAPTHTTRAB9AGAA | |
| SCHEMBL30679054 | 0.81 | MAPK1 (0.53) | ALDH1A1MAPTHTTRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2025-03-25 | — | — | US | disclosed |
| WO-2025012057-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-06 | — | — | US | disclosed |
| EP-4382511-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| EP-2521726-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2011086306-A9 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349996-A1 | 1-PHENYLPYRROLE COMPOUNDS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011086306-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, EGFR | TDP1 2170/4885ATM 2569/4885HSPB1 2220/4885 |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | TDP1 3856/4885ATM 3491/4885HSPB1 1404/4885 |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | TDP1 1074/4885ATM 1836/4885HSPB1 3602/4885 |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | TDP1 1166/4885ATM 304/4885HSPB1 411/4885 |
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | ERBB4, EGFR, ERBB2 | TDP1 3430/4885ATM 726/4885HSPB1 1998/4885 |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | TDP1 600/4885ATM 132/4885HSPB1 2147/4885 |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CAMKK1, CAMKK2, CAMK1 | TDP1 1123/4885ATM 2272/4885HSPB1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.